Perrigo Recalls Acne Medicine on Mold IssuesBy
Perrigo has issued a voluntary Class II recall of 162,534 tubes of clindamycin phosphate and benzoyl peroxide gel, a prescription acne medication, due to mold contamination. Perrigo initiated the recall in December 2016, and the recall was noted in the January 18, 2017 US Food and Drug Administration Weekly Enforcement Report. The report noted that a small number of tubes may include the presence of mold on the cap.
A Class II recall involves products that might cause a temporary health problem, or pose only a slight threat of a serious nature.
The recall applies to prescription-only clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% in 45-gram tubes. The product is manufactured by Perrigo at its facility in Yeruham, Israel and is distributed by Perrigo in Allegan, Michigan.
Perrigo’s product is the generic version of Duac (benzoyl peroxide; clindamycin phosphate) by Stiefel, a GlaxoSmithKline skin healthcare company based in Middlesex, UK.
Source: Food and Drug Administration